Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-924-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: other: clastogenicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2011-09-14 to 2012-02-23
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5375 - In vitro Mammalian Chromosome Aberration Test
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- Phosphoric acid, dodecyl ester, potassium salt
- EC Number:
- 254-414-3
- EC Name:
- Phosphoric acid, dodecyl ester, potassium salt
- Cas Number:
- 39322-78-6
- Molecular formula:
- not applicable
- IUPAC Name:
- Reaction mass of potassium didodecylphosphate and dipotassium dodecylphosphate and water
- Test material form:
- semi-solid (amorphous): gel
- Remarks:
- migrated information: paste
Constituent 1
Method
Species / strain
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Details on mammalian cell type (if applicable):
- - Type and identity of media: MEM
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes
- Metabolic activation:
- with and without
- Metabolic activation system:
- Liver S9 of Wistar phenobarbital and ß-naphthoflavone-induced rat liver S9 mix
- Test concentrations with justification for top dose:
- Pre-experiment:
with and without metabolic activation: 7.8, 15.6, 31.3, 62.5, 125, 250, 500, 1000, 2500 and 5000 µg/mL
Experiment I:
without metabolic activation: 15.6, 250, 500 and 1000 µg/mL
with metabolic activation: 15.6, 500, 1000 and 1500 µg/mL
Experiment II:
without metabolic activation: 15.6, 31.3, 62.5 and 125.0 µg/mL
with metabolic activation: 900, 1600 and 1800 µg/mL - Vehicle / solvent:
- -Vehicle (s)/solvent(s) used: cell culture medium (MEM)
-Justification for choice of solvent/vehicle: The test item was prepared in cell culture medium followed by ultrasound for around 5 minutes prior to treatment. After that the test item was well suspended. The solvent was compatible with the survival of the cells and the S9 activity.
Controlsopen allclose all
- Untreated negative controls:
- yes
- Positive controls:
- yes
- Positive control substance:
- ethylmethanesulphonate
- Remarks:
- without metabolic activation Migrated to IUCLID6: 400 and 900 µg/mL
- Positive control substance:
- cyclophosphamide
- Remarks:
- with metabolic activation Migrated to IUCLID6: 0.83 µg/mL
- Details on test system and experimental conditions:
- TREATMENT TIME:
4 hours (Experiment I with and without metabolic activation, experiment II with metabolic activation)
20 hours (Experiment II without metabolic activation)
FIXATION INTERVAL: 20 hours (Experiment I and II with and without metabolic activation)
NUMBER OF REPLICATIONS: 2 independent experiments
NUMBER OF CELLS SEEDED: 1 x 10^4 - 5 x 10^4 cells
NUMBER OF CULTURES: two cultures per concentration
NUMBER OF CELLS SCORED: 200 cells per concentration (100 cells per culture)
except for 15.6 µg/mL (experiment I with metabolic activation) and 31.3 µg/mL (experiment II without metabolic activation): 300 cells
DETERMINATION OF CYTOTOXICITY: Mitotic index, cell density - Evaluation criteria:
- There are several criteria for determining a positive result:
- a clear and dose-related increase in the number of cells with aberrations,
- a biologically relevant response for at least one of the dose groups, which is higher than the laboratory negative control range (0.0% - 4.0% aberrant cells (with and without metabolic activation)). - Statistics:
- According to OECD guidelines, the biological relevance of the results is the criterion for the interpretation of results, a statistical evaluation of the results is not regarded as necessary.
Results and discussion
Test results
- Key result
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
Any other information on results incl. tables
Results of chromosome analysis | |||||||||||||||
without metabolic activation | |||||||||||||||
Cytotoxicity | Chromatid aberrations | Isochromatid aberrations | rel. Mitotic index (%) | rel. Cell density (%) | Poly-ploidy | mean % aberrant cells | |||||||||
Scored cells | gaps | breaks | inter-changes | other | gaps | breaks | inter-changes | other | incl. Gaps | excl. Gaps | |||||
Experiment I | |||||||||||||||
negative control | 200 | - | 5 | 4 | 0 | 0 | 0 | 0 | 1 | 1 | 100 | 100 | 2 | 4.5 | 2.5 |
15.6 µg/mL | 200 | no | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 103 | 96 | 3 | 2.5 | 0.0 |
250 µg/mL | 200 | no | 6 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 81 | 78 | 3 | 3.5 | 1.5 |
500 µg/mL | 200 | yes | 4 | 3 | 2 | 0 | 0 | 0 | 2 | 0 | 53 | 55 | 1 | 5.0 | 3.0 |
1000 µg/mL | 200 | yes | 4 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 51 | 44 | 0 | 3.0 | 0.5 |
EMS (900 µg/mL) | 200 | - | 7 | 10 | 8 | 2 | 0 | 1 | 2 | 0 | 85 | 94 | 3 | 12.5 | 9.5 |
Experiment II | |||||||||||||||
negative control | 200 | - | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 2 | 2.5 | 2.0 |
15.6 µg/mL | 200 | no | 6 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 76 | 102 | 3 | 4.5 | 2.0 |
31.3 µg/mL | 300 | no | 5 | 7 | 1 | 1 | 0 | 0 | 0 | 0 | 74 | 94 | 1 | 4.7 | 3.0 |
62.5 µg/mL | 200 | yes | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 51 | 89 | 1 | 2.5 | 1.5 |
125.0 µg/mL | 200 | yes | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 30 | 57 | 1 | 2.0 | 1.5 |
EMS (400 µg/mL) | 200 | - | 7 | 17 | 3 | 3 | 3 | 0 | 0 | 0 | 72 | 103 | 0 | 13.0 | 10.5 |
Results of chromosome analysis | |||||||||||||||
with metabolic activation | |||||||||||||||
Cytotoxicity | Chromatid aberrations | Isochromatid aberrations | rel. Mitotic index (%) | rel. Cell density (%) | Poly-ploidy | mean % aberrant cells | |||||||||
Scored cells | gaps | breaks | inter-changes | other | gaps | breaks | inter-changes | other | incl. Gaps | excl. Gaps | |||||
Experiment I | |||||||||||||||
negative control | 200 | - | 6 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 4.0 | 1.0 |
15.6 µg/mL | 300 | no | 4 | 3 | 3 | 1 | 0 | 0 | 2 | 0 | 96 | 102 | 1 | 4.0 | 3.0 |
500 µg/mL | 200 | no | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 90 | 86 | 0 | 2.0 | 1.0 |
1000 µg/mL | 200 | yes | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62 | 85 | 1 | 1.5 | 0.0 |
1500 µg/mL | 200 | yes | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 54 | 63 | 1 | 2.0 | 0.5 |
CPA (0.83 µg/mL) | 200 | - | 3 | 12 | 11 | 1 | 0 | 1 | 1 | 0 | 104 | 85 | 3 | 12.0 | 10.5 |
Experiment II | |||||||||||||||
negative control | 200 | - | 4 | 5 | 0 | 1 | 1 | 0 | 1 | 0 | 100 | 100 | 2 | 5.5 | 3.5 |
900 µg/mL | 200 | no | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 88 | 0 | 2.0 | 1.5 |
1600 µg/mL | 200 | yes | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 54 | 75 | 0 | 2.5 | 1.5 |
1800 µg/mL | 200 | yes | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 45 | 56 | 0 | 1.5 | 1.5 |
CPA (0.83 µg/mL) | 200 | - | 3 | 9 | 3 | 3 | 1 | 1 | 2 | 1 | 96 | 100 | 0 | 10.0 | 9.0 |
Applicant's summary and conclusion
- Conclusions:
- In conclusion, it can be stated that during the described in vitro chromosome aberration test and under the experimental conditions reported, the test item (CAS39322-78-6) did not induce structural chromosomal aberrations in the V79 Chinese hamster cell line.
Therefore, the test item is considered to be non-clastogenic in this chromosome aberration test. - Executive summary:
To investigate the potential of Afilan V5756 to induce structural chromosome aberrations in Chinese hamster V79 cells, anin vitrochromosome aberration assay was carried out.
The chromosomes were prepared 20 h after start of treatment with the test item. The treatment interval was 4 h with and without metabolic activation in experiment I. In experiment II, the treatment interval was 4 h with and 20 h without metabolic activation.
Duplicate cultures were treated at each concentration. 100 metaphases per culture were scored for structural chromosomal aberrations, except for 15.6 µg/mL (experiment I with metabolic activation) and 31.3 µg/mL (experiment II without metabolic activation): 200 cells for the 1st culture and 100 cells for the 2nd culture.
The test item was prepared in cell culture medium followed by ultrasound for around 5 minutes prior to treatment. After that the test item was well suspended.
The following concentrations were evaluated for the microscopic analysis of chromosomal aberrations:
Experiment I:
without metabolic activation: 15.6, 250, 500 and 1000 µg/mL
with metabolic activation: 15.6, 500, 1000 and 1500 µg/mL
Experiment II:
without metabolic activation: 15.6, 31.3, 62.5 and 125.0 µg/mL
with metabolic activation: 900, 1600 and 1800 µg/mL
Precipitation of the test item was observed with and without metabolic activation in both experiments.
Toxic effects of the test item were observed in experiment I without metabolic activation at concentrations of 500 µg/mL and higher, with metabolic activation at concentrations of 1000 µg/mL and higher. In experiment II without metabolic activation (long time exposure) toxic effects of the test item were observed at concentrations of 62.5 µg/mL and higher, with metabolic activation at concentrations of 1600 µg/mL and higher.
In both experiments, no biologically relevant increase of the aberration rates was noted after treatment with the test item with and without metabolic activation. The aberration rates of all dose groups treated with the test item were within the historical control data of the negative control.
In the experiments I and II with and without metabolic activation no biologically relevant increase in the frequencies of polyploid cells was found after treatment with the test item as compared to the controls.
EMS (400 and 900 µg/mL) and CPA (0.83 µg/mL) were used as positive controls and induced distinct and biologically relevant increases in cells with structural chromosomal aberrations.
The positive controls induced the appropriate responses.
There was no evidence of Afilan V5756 induced over background.
This study is classified as acceptable. This study satisfies the requirement for Test Guideline OPPTS 870.5375; OECD 473 for in vitro cytogenetic mutagenicity data.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.